Asota avacta

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Retrieved on: 
Monday, January 9, 2023
CRUK, Roche, Sanofi, SVP, University, London Business School, Therapy, Chemical engineering, New product development, Master of Science, Northwestern University, Biomedical Research, Biopharmaceutical, Berkeley, Medicine, Senior, Drug development, ReNeuron, Academy of Medical Sciences (United Kingdom), CSO, BS, University of Oxford, SABS, Acquisition, European, MBA, Doctor of Philosophy, GSK, Venture capital, BioMarin Pharmaceutical, University of Cambridge, Management, Fine chemical, Pharma, Biotechnology, Asota avacta

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

Key Points: 
  • LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.
  • Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs.
  • Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi.
  • Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche.

Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

Retrieved on: 
Monday, September 5, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Safety, Pharmacokinetics, Neoplasm, AIM, Degenerative disease, Sarcoma, Disease, US Foods, American Cancer Society, Food, ODD, Soft-tissue sarcoma, FDA, Radiation, Group, Orphan drug, Plasma protein binding, Adult, Doxorubicin, Review, Patient, Pharmaceutical industry, Medical imaging, Asota avacta

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the companys lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the companys lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
  • This designation qualifies the developer of the drug for certain incentives, including, seven years of market exclusivity upon drug approval from the FDA.
  • This designation provides tax credits and other incentives for drug developers addressing rare diseases.
  • Most notably the Orphan Drug Designation will give Avacta, if AVA6000 is approved for treatment of soft tissue sarcoma, seven years of market exclusivity in the US, which is a significant commercial advantage.

LG Chem Renews License Triggering Payment to Avacta

Retrieved on: 
Thursday, June 30, 2022
Research, Communications, Clinical Trials, Media, Biotechnology, Health, Pharmaceutical, Science, Oncology, AIM, Investigational New Drug, LG Corporation, Affimer, Blood, Partnership, Technology, IND, LG Chem, Drug development, Group, Pharmaceutical industry, Asota avacta

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million.
  • Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avactas Affimer PD-L1 inhibitor with Affimer XT serum half-life extension for a range of indications.
  • LG Chem has exercised its license renewal option and will progress the PD-L1/XT candidate by commencing pre-clinical studies which are intended to form the basis of an Investigational New Drug (IND) submission.
  • In December 2018, Avacta and LG Chem entered into a multi-target development agreement to develop Affimer therapeutics in several disease areas.

Paul Fry appointed as Argenta’s new Chief Financial Officer

Retrieved on: 
Monday, June 27, 2022
Health, Research, Pharmaceutical, Science, Biotechnology, Veterinary, Gavin Downie, Acquisition, Vodafone, CEO, GSK, Research, KKR, Contract research organization, Telecommunication, Growth, Ownership, TCR, GMP, CDMO, CRO, CFO, Contract, London Stock Exchange, United Kingdom, Partnership, Asota avacta, Chartered Institute of Management Accountants, Technology, Management accounting, Vectura Group, University of Oxford, Health, Audit committee, Time, List of professional associations in the United Kingdom, Management, Renewable energy

Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.

Key Points: 
  • Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately.
  • Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications.
  • Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology.
  • Paul Fry said: It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta.

AffyXell Expands its Strategic Partnership With GenScript ProBio

Retrieved on: 
Monday, May 16, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DNA, HKG, Lentivirus, Patient, Daewoong Pharmaceutical, CDMO, Stem cell, GenScript Biotech, Research, Partnership, AIM, Group, Fine chemical, Pharmaceutical industry, Vaccine, Asota avacta

AffyXell and GenScript ProBio are extending their strategic manufacturing partnership, which they entered into in December 2021, that covers AffyXells first drug development programme to include additional future programmes.

Key Points: 
  • AffyXell and GenScript ProBio are extending their strategic manufacturing partnership, which they entered into in December 2021, that covers AffyXells first drug development programme to include additional future programmes.
  • Dr Alastair Smith, Chief Executive Officer of Avacta, commented: This is an important strategic partnership for AffyXell with a world leading contract development and manufacturing partner.
  • The fact that GenScript ProBio are prepared to take a strategic equity stake in AffyXell is a very strong validation of the potential for AffyXells next generation cell and gene therapies, and the future valuation of the business.
  • Dr Brian Min, Chief Executive Officer of GenScript ProBio commented: We are pleased to partner with AffyXell and are honored to support this next-generation cell therapy project with GenScript ProBios stable and high-yield viral vector platform.

Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

Retrieved on: 
Wednesday, April 13, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Daewoong Pharmaceutical, Group, Intellectual property, AIM, Medication, B cell, Therapy, MSC, Pharmaceutical industry, Fine chemical, Asota avacta

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avactas shareholding in AffyXell Therapeutics (AffyXell), a joint venture between Avacta and Daewoong Pharmaceutical (Daewoong) in South Korea.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avactas shareholding in AffyXell Therapeutics (AffyXell), a joint venture between Avacta and Daewoong Pharmaceutical (Daewoong) in South Korea.
  • Avacta has successfully developed and characterised Affimer proteins against the first target for AffyXell and has now transferred intellectual property relating to Affimer proteins against that target into AffyXell, triggering an agreed milestone in the joint venture agreement.
  • In exchange for this, Avacta has received an increase in its equity stake in AffyXell, which was diluted from its founding equity stake in February 2021 when AffyXell completed a Series A financing of $7.3 million from a group of venture funds in February 2021.
  • AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (MSC) therapies.

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

Retrieved on: 
Monday, March 21, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Rubius, Drug development, Therapy, Leadership, Group, Board, IND, Biotechnology, TCR, University, Drug discovery, Pfizer, Knowledge, Immunocore, Patient, AIM, Pharmaceutical industry, Management, Asota avacta

Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.

Key Points: 
  • Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.
  • Dr. Christina Coughlin, commented: I find the Affimer and pre|CISION platforms to be highly innovative in the oncology field.
  • Dr. Alastair Smith, Chief Executive Officer of Avacta Group, commented: I am very pleased, indeed, to welcome Christina to Avacta and the Board.
  • Dr. Eliot Forster, Chairman of Avacta Group, commented: I am delighted that Christina will be joining the Board of Avacta.

Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

Retrieved on: 
Wednesday, December 22, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Technology, CE, Viral load, Medusa, Power-on self-test, Carlos, Group, AIM, Asota avacta, Adoption, Medical device, Vaccine, EU

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, announces that the AffiDX SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, announces that the AffiDX SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.
  • Avacta partnered with Medusa Healthcare (Medusa) to obtain regulatory approval for the AffiDX antigen test for consumer self-testing and has now received the CE mark from a European Notified Body.
  • The AffiDX antigen lateral flow test was CE marked for professional use in the UK and EU in June 2021.
  • Dr. Alastair Smith, Chief Executive of Avacta Group, commented: This is an extremely important step forwards in the commercialisation of the AffiDX antigen test.

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Retrieved on: 
Monday, November 29, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Patient, Safety, Therapeutic index, Asota avacta, US Foods, Company, Group, Clinical trial, IND, Cardiotoxicity, Anthracycline, Incidence, FDA, FAP, Standard of care, AIM, Toxicity, Food, Aplastic anemia, Pharmaceutical industry, Medical imaging

This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.

Key Points: 
  • This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.
  • AVA6000 is a novel form of doxorubicin that has been modified with Avactas pre|CISION platform to improve its safety and therapeutic index.
  • This allows Avacta to enroll eligible patients into US clinical trial sites for the companys Phase I multi-centre study, ALS-6000-101.
  • Dr. Alastair Smith, Chief Executive of Avacta Group, commented: We are delighted to have received approval from the FDA to add clinical trial sites in the United States as part of the Phase I study for AVA6000.

Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

Retrieved on: 
Wednesday, September 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Partnership, Asota avacta, Half-life, Therapy, AIM, LG Chem, Serum albumin, LG Corporation, Group, Neoplasm, Pharmaceutical industry

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a pre-clinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, triggering an undisclosed milestone payment.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a pre-clinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, triggering an undisclosed milestone payment.
  • Avacta and LG Chem have a multi-target therapeutics development agreement to develop Affimer therapeutics in several disease areas.
  • In addition, under the agreement Avacta will earn royalties on all future Affimer XT product sales by LG Chem.
  • Dr. Alastair Smith, Chief Executive of Avacta Group, commented: I am delighted with the progress in our important strategic partnership with LG Chem.